FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2762701444> ?p ?o ?g. }

• W2762701444 endingPage "v292" @default.
• W2762701444 startingPage "v291" @default.
• W2762701444 abstract "Background: While androgen-deprivation therapy (ADT) demonstrates antitumor activity in mHSPC with prolonged disease control, resistance ultimately occurs and patients die of castration-resistant PC (CRPC). Approximately 10-50% of PC subjects develop CRPC in < 5 yr. Chemohormonal therapy per ESMO guidelines is recommended as first-line treatment of metastatic, castration-naïve disease in men fit enough for chemotherapy. Darolutamide (ODM-201) is a unique investigational oral androgen receptor (AR) antagonist that binds the AR and AR mutants (eg, W742L and F877L) with high affinity and selectivity, thus, inhibiting receptor function and dihydrotestosterone binding with negligible blood-brain barrier penetration. In the phase 1/2 ARADES and ARAFOR trials, darolutamide had antitumor activity and was well tolerated in men with mCRPC (Fizazi et al. Lancet Oncol 2014; Massard et al. Eur Urol 2016). As a result of this encouraging activity in mCRPC, the ARASENS trial is evaluating darolutamide plus standard ADT + docetaxel in men with mHSPC. Trial design: This international, randomized, double-blind, placebo-controlled, phase 3 trial (NCT02799602) is being conducted in 23 countries. 1300 men with newly diagnosed mHSPC will be randomized 1:1 to either 600 mg (2 × 300 mg) darolutamide BID with food, equivalent to a total daily dose of 1200 mg or placebo, both with ADT + docetaxel (6 cycles after randomization), and stratified by extent of disease and alkaline phosphatase levels. Key inclusion criteria are confirmed PC with documented metastases, started ADT ± first-generation androgen inhibition therapy ≤12 wk before randomization, and Eastern Cooperative Oncology Group performance status 0 or 1. The primary objective is to show superior overall survival with darolutamide vs placebo, both with ADT + docetaxel. Secondary end points include time to CRPC, initiation of subsequent anticancer therapy, symptomatic skeletal event-free survival (SSE-FS), time to first SSE, initiation of opioid use, pain progression, and worsening of physical symptoms, all measured at 12-wk intervals. Safety will be assessed. The trial is open for enrollment, FPFV was in November 2016, and >110 sites in 16 countries are enrolling. Clinical trial identification: NCT02799602 Legal entity responsible for the study: Bayer Funding: Funded by Bayer. Darolutamide was discovered at Orion Corporation and is being jointly developed with Bayer. Disclosure: M.R. Smith: Consultant for Bayer and Janssen. F. Saad: Consultant, honoraria, research funding from Bayer, Sanofi, Janssen, and Astellas. M. Hussain: Contract to conduct the clinical trial. C.N. Sternberg: Personal fees from Janssen, Sanofi, Astellas, Clovis, Bayer, and Ferring, outside the submitted work. K. Fizazi: Honoraria from Astellas, AstraZeneca, Bayer, Clovis, Curevac, Genentech, Janssen, Orion, and Sanofi. E.D. Crawford: Consultant for Bayer, MDx, Genomic Health, Janssen, Dendreon, and Ferring; honoraria from Bayer and involved in trials with the NIH and University of Colorado Cancer Center; family member employed by Dendreon. K. Yamada: Employee of Bayer US. C. Kappeler: Employee of Bayer AG and own Bayer shares. I. Kuss: Employee of Bayer AG. B. Tombal: Grants and other fees received from Bayer, Astellas, Ferring, and Sanofi; personal fees from Medivation and Janssen." @default.
• W2762701444 created "2017-10-20" @default.
• W2762701444 creator A5004985848 @default.
• W2762701444 creator A5007779528 @default.
• W2762701444 creator A5014213335 @default.
• W2762701444 creator A5017925159 @default.
• W2762701444 creator A5020692060 @default.
• W2762701444 creator A5027342364 @default.
• W2762701444 creator A5040519604 @default.
• W2762701444 creator A5041126882 @default.
• W2762701444 creator A5049695468 @default.
• W2762701444 creator A5053749991 @default.
• W2762701444 date "2017-09-01" @default.
• W2762701444 modified "2023-10-01" @default.
• W2762701444 title "ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC)" @default.
• W2762701444 doi "https://doi.org/10.1093/annonc/mdx370.055" @default.
• W2762701444 hasPublicationYear "2017" @default.
• W2762701444 type Work @default.
• W2762701444 sameAs 2762701444 @default.
• W2762701444 citedByCount "1" @default.
• W2762701444 countsByYear W27627014442023 @default.
• W2762701444 crossrefType "journal-article" @default.
• W2762701444 hasAuthorship W2762701444A5004985848 @default.
• W2762701444 hasAuthorship W2762701444A5007779528 @default.
• W2762701444 hasAuthorship W2762701444A5014213335 @default.
• W2762701444 hasAuthorship W2762701444A5017925159 @default.
• W2762701444 hasAuthorship W2762701444A5020692060 @default.
• W2762701444 hasAuthorship W2762701444A5027342364 @default.
• W2762701444 hasAuthorship W2762701444A5040519604 @default.
• W2762701444 hasAuthorship W2762701444A5041126882 @default.
• W2762701444 hasAuthorship W2762701444A5049695468 @default.
• W2762701444 hasAuthorship W2762701444A5053749991 @default.
• W2762701444 hasBestOaLocation W27627014441 @default.
• W2762701444 hasConcept C121608353 @default.
• W2762701444 hasConcept C126322002 @default.
• W2762701444 hasConcept C142724271 @default.
• W2762701444 hasConcept C143998085 @default.
• W2762701444 hasConcept C168563851 @default.
• W2762701444 hasConcept C204243189 @default.
• W2762701444 hasConcept C204787440 @default.
• W2762701444 hasConcept C27081682 @default.
• W2762701444 hasConcept C2776694085 @default.
• W2762701444 hasConcept C2777899217 @default.
• W2762701444 hasConcept C2780192828 @default.
• W2762701444 hasConcept C2781190966 @default.
• W2762701444 hasConcept C61367390 @default.
• W2762701444 hasConcept C71924100 @default.
• W2762701444 hasConceptScore W2762701444C121608353 @default.
• W2762701444 hasConceptScore W2762701444C126322002 @default.
• W2762701444 hasConceptScore W2762701444C142724271 @default.
• W2762701444 hasConceptScore W2762701444C143998085 @default.
• W2762701444 hasConceptScore W2762701444C168563851 @default.
• W2762701444 hasConceptScore W2762701444C204243189 @default.
• W2762701444 hasConceptScore W2762701444C204787440 @default.
• W2762701444 hasConceptScore W2762701444C27081682 @default.
• W2762701444 hasConceptScore W2762701444C2776694085 @default.
• W2762701444 hasConceptScore W2762701444C2777899217 @default.
• W2762701444 hasConceptScore W2762701444C2780192828 @default.
• W2762701444 hasConceptScore W2762701444C2781190966 @default.
• W2762701444 hasConceptScore W2762701444C61367390 @default.
• W2762701444 hasConceptScore W2762701444C71924100 @default.
• W2762701444 hasLocation W27627014441 @default.
• W2762701444 hasOpenAccess W2762701444 @default.
• W2762701444 hasPrimaryLocation W27627014441 @default.
• W2762701444 hasRelatedWork W2299690226 @default.
• W2762701444 hasRelatedWork W2770702948 @default.
• W2762701444 hasRelatedWork W3023947295 @default.
• W2762701444 hasRelatedWork W3156855168 @default.
• W2762701444 hasRelatedWork W3200282916 @default.
• W2762701444 hasRelatedWork W4205706045 @default.
• W2762701444 hasRelatedWork W4226303148 @default.
• W2762701444 hasRelatedWork W4229076799 @default.
• W2762701444 hasRelatedWork W4295154856 @default.
• W2762701444 hasRelatedWork W4297472852 @default.
• W2762701444 hasVolume "28" @default.
• W2762701444 isParatext "false" @default.
• W2762701444 isRetracted "false" @default.
• W2762701444 magId "2762701444" @default.
• W2762701444 workType "article" @default.